[HTML][HTML] Enzalutamide for the treatment of androgen receptor–expressing triple-negative breast cancer
TA Traina, K Miller, DA Yardley, J Eakle… - Journal of clinical …, 2018 - ncbi.nlm.nih.gov
TA Traina, K Miller, DA Yardley, J Eakle, LS Schwartzberg, J O'Shaughnessy, W Gradishar…
Journal of clinical oncology, 2018•ncbi.nlm.nih.govPurpose Studies suggest that a subset of patients with triple-negative breast cancer (TNBC)
have tumors that express the androgen receptor (AR) and may benefit from an AR inhibitor.
This phase II study evaluated the antitumor activity and safety of enzalutamide in patients
with locally advanced or metastatic AR-positive TNBC.
have tumors that express the androgen receptor (AR) and may benefit from an AR inhibitor.
This phase II study evaluated the antitumor activity and safety of enzalutamide in patients
with locally advanced or metastatic AR-positive TNBC.
Abstract
Purpose
Studies suggest that a subset of patients with triple-negative breast cancer (TNBC) have tumors that express the androgen receptor (AR) and may benefit from an AR inhibitor. This phase II study evaluated the antitumor activity and safety of enzalutamide in patients with locally advanced or metastatic AR-positive TNBC.
ncbi.nlm.nih.gov